Pipeline

December 3, 2018

Company	Drug/Device	Medical Condition	Status
GlycoMimetics	Uproleselan (GMI-1271)	Relapsed/refractory acute myeloid leukemia	First patient enrolled in global Phase III trial
Sollis Therapeutics	Clonidine micropellet	Sciatica pain	First patient enrolled in the RePRIEVE-CM trial
Stallergenes Greer	Sublingual allergy immunotherapy tablet STAGR320	House dust mite (HDM)-induced allergic rhinitis	Phase III trial met its primary endpoint with statistical significance in patients treated with STAGR320 compared to patients on placebo
Rocket Pharmaceuticals	RP-L201	Severe Leukocyte Adhesion Deficiency-I	FDA approved IND for Phase I trial
Pliant Therapeutics	PLN-74809	Primary sclerosing cholangitis	Granted Orphan Drug designation by FDA
Allergan	Avycaz	Complicated urinary tract infections and complicated intra-abdominal infections	FDA accepted for review sNDA to expand label indication
NovImmune S.A.	Gamifant® (emapalumab-lzsg)	Primary hemophagocytic lymphohistiocytosis	Granted approval by FDA
Pfizer	Daurismo™ (glasdegib), to be used in combination with low-dose cytarabine (LDAC)	Newly diagnosed acute myeloid leukemia in adults 75 years or older	Granted approval by FDA
AbbVie and Genentech	Venclexta® (venetoclax)	Newly diagnosed acute myeloid leukemia in adults 75 years or older who cannot tolerate intensive chemotherapy	Granted accelerated approval by FDA
Synthetic Biologics	Synthetic Biologics	Antibiotic-mediated Clostridium difficile infection	Successfully completed End-of-Phase II meeting; Phase III go-ahead from FDA
Bayer and Loxo Oncology	Vitrakvi (larotrectinib)	Solid tumors with NTRK gene fusion	Granted approval by FDA
HighTide Therapeutics	HTD1801	Nonalcoholic steatohepatitis	Fast Track designation granted by FDA